<DOC>
	<DOCNO>NCT00381368</DOCNO>
	<brief_summary>The purpose study determine efficacy safety three time repeat load dose intravenous ibandronate ( ibandronic acid ) , 6 mg , breast cancer patient painful skeletal metastasis .</brief_summary>
	<brief_title>Safety Efficacy Study Intravenous Loading Dose Ibandronate Breast Cancer Patients</brief_title>
	<detailed_description>Painful skeletal metastasis common site advanced disease . For instance , breast cancer , despite cancer treatment ( radiotherapy , cytotoxic treatment adequate treatment pain ) , patient often need additional treatment may relieve symptom . Bisphosphonates , ibandronic acid , pilot study show significant decrease pain score , load dose long-term treatment . In study safety efficacy intravenous load dose three time 6 mg ibandronate three consecutive day breast cancer patient painful skeletal metastasis study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>Breast cancer presence bone metastases Pain score 4 VAS Patients pathological fracture medulla compression neuropathic pain Patients infection corticosteroid treatment Pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>skeletal metastasis</keyword>
	<keyword>bisphosphonate therapy</keyword>
	<keyword>Breast cancer painful skeletal metastasis</keyword>
</DOC>